Molly A. McGlynn

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.

Leonard Buckbinder, Jacquelyn Klug-McLeod, Angel Guzman-Perez, 2008, Bioorganic & medicinal chemistry letters.

Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.

Christopher S. Poss, M. Hayward, J. Driscoll, 2007, Bioorganic & medicinal chemistry letters.

CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases*

Christopher S. Poss, J. Kath, W. Brissette, 2003, Journal of Biological Chemistry.

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity.

Li Xing, Leonard Buckbinder, Amy Baumann, 2009, Bioorganic & medicinal chemistry letters.